Case: Patents/Injunctions (Fed. Cir.)

The Federal Circuit reversed the decision of the District of New Jersey granting Incyte Corporation and Incyte Holdings Corporation’s motion for a preliminary injunction enjoining Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Inc. from making, using, selling, advertising, or distributing its drug Leqselvi, in this action for infringement of Incyte’s patent that claims deuterated versions of ruxolitinib. According to the appeals court, the district court clearly erred in its irreparable harm analysis.